Z-VDVAD-FMK

Z-VDVAD-FMK is a special inhibitor of caspase-2. Z-VDVAD-FMK produces a reduction in Lovastatin-induced apoptosis[1][2][3].

Product Specifications

CAS Number

[210344-92-6]

Product Name Alternative

Z-VD (OMe) VAD (OMe) -FMK

UNSPSC

12352209

Target

Caspase

Type

Peptides

Related Pathways

Apoptosis

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/z-vdvad-fmk.html

Purity

98.0

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](C(C)C)C(N[C@@H](CC(OC)=O)C(N[C@H](C(N[C@@H](C)C(N[C@H](C(CF)=O)CC(OC)=O)=O)=O)C(C)C)=O)=O)OCC1=CC=CC=C1

Molecular Formula

C32H46FN5O11

Molecular Weight

695.73

References & Citations

[1]S Gamen, et al. Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp Cell Res. 2000 Jul 10;258 (1) :223-35. |[2]Cédric Sapet, et al. Thrombin-induced endothelial microparticle generation: identification of a novel pathway involving ROCK-II activation by caspase-2. Blood. 2006 Sep 15;108 (6) :1868-76. |[3]Simon W Rabkin, et al. Lovastatin-induced cardiac toxicity involves both oncotic and apoptotic cell death with the apoptotic component blunted by both caspase-2 and caspase-3 inhibitors. Toxicol Appl Pharmacol. 2003 Dec 15;193 (3) :346-55.